China Pharma Holdings, Inc. Reports Third Quarter 2020 Financial Results
Rhea-AI Summary
China Pharma Holdings, Inc. (CPHI) announced its Q3 2020 financial results, reporting revenue of $2.4 million, unchanged from Q3 2019. Gross margin plunged to 2.0% from 15.7% year-over-year, with a net loss of $1.0 million compared to $0.7 million in the prior year. The operational loss also increased to $1.0 million. For the nine months ending September 30, 2020, total revenue stayed at $7.9 million, with a reduced net loss of $1.7 million versus $2.0 million in 2019. The decrease in net loss was aided by a foreign trade deal involving COVID-19 testers.
Positive
- Reduced net loss from $2.0 million to $1.7 million over nine months.
- Improved gross profit margin from 15.1% to 17.5% for nine months due to foreign trade.
Negative
- Gross margin fell sharply from 15.7% to 2.0% in Q3 2020.
- Increased operating loss from $0.6 million to $1.0 million in Q3 2020.
- Cash and cash equivalents decreased to $0.3 million from $1.1 million since the end of 2019.
News Market Reaction – CPHI
On the day this news was published, CPHI gained 0.22%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
HAIKOU, China, Nov. 13, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended September 30, 2020.
Third Quarter Highlights
- Revenue was
$2.4 million in the third quarter of 2020, which stayed the same as the condition in the same period of 2019; - Gross margin was
2.0% in the third quarter of 2020, compared to15.7% in the same period of 2019; - Loss from operations was
$1.0 million in the third quarter of 2020 compared to$0.6 million in the same period of 2019; - Net loss was
$1.0 million in the third quarter of 2020 compared to$0.7 million in the same period of 2019. Loss per common stock was both$0.02 per basic and diluted share in the third quarter 2020 and 2019, respectively.
Ms. Zhilin Li, China Pharma's Chairwoman and CEO, commented, "Since the outbreak of COVID-19 early this year, it has continued to create a substantial negative impact on sales of pharmaceutical companies, including ours. Nevertheless, we achieved comparable drug sales revenue in the third quarter of 2020 compared to the same period last year, which showed certain improvements from the sales performance in the previous quarter (the second quarter of 2020), thanks to the efforts of the management and sales teams." Ms. Li continued, "We will continue to work on improving human health and we aim to leverage our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical and comprehensive healthcare products for the benefit of human health."
Third Quarter Results
Revenue was both
For the three months ended September 30, 2020, our cost of revenue was
Gross profit for the three months ended September 30, 2020 was
Our selling expenses for the three months ended September 30, 2020 and 2019 were
Our general and administrative expenses were both
Our operating loss for the three months ended September 30, 2020 was
Net loss for the three months ended September 30, 2020 was
Nine Months Results
Revenue was both
For the nine months ended September 30, 2020, our cost of revenue was
Gross profit for the nine months ended September 30, 2020 was
Net loss for the nine months ended September 30, 2020 was
Financial Condition
As of September 30, 2020, the Company had cash and cash equivalents of
Our net accounts receivable was
For the nine months ended September 30, 2020, cash flow used in operating activities was
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnique Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
- FINANCIAL TABLES FOLLOW -
CHINA PHARMA HOLDINGS, INC. | ||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
(Unaudited) | ||||
September 30, | December 31, | |||
2020 | 2019 | |||
ASSETS | ||||
Current Assets: | ||||
Cash and cash equivalents | $ 346,611 | $ 1,074,979 | ||
Restricted cash | - | 109,908 | ||
Banker's acceptances | 38,465 | 45,756 | ||
Trade accounts receivable, less allowance for doubtful | ||||
accounts of | 535,060 | 635,371 | ||
Other receivables, less allowance for doubtful | ||||
accounts of | 91,389 | 46,643 | ||
Advances to suppliers | 106,880 | 404 | ||
Inventory | 3,513,570 | 3,588,824 | ||
Prepaid expenses | 401,747 | 77,120 | ||
Total Current Assets | 5,033,722 | 5,579,005 | ||
Property, plant and equipment, net | 15,836,890 | 16,313,827 | ||
Operating lease right of use asset | 70,733 | 136,779 | ||
Intangible assets, net | 183,545 | 205,611 | ||
TOTAL ASSETS | $ 21,124,890 | $ 22,235,222 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
Current Liabilities: | ||||
Trade accounts payable | $ 989,641 | $ 1,366,330 | ||
Accrued expenses | 160,535 | 189,880 | ||
Other payables | 3,483,821 | 3,560,332 | ||
Advances from customers | 640,103 | 505,398 | ||
Other payables - related parties | 2,176,629 | 2,071,986 | ||
Operating lease liability, current portion | 73,690 | 91,306 | ||
Current portion of construction loan facility | 2,202,611 | 2,150,168 | ||
Current portion of lines of credit | 1,827,189 | - | ||
Bankers' acceptance notes payable | - | 109,908 | ||
Total Current Liabilities | 11,554,219 | 10,045,308 | ||
Non-current Liabilities: | ||||
Construction loan facility | - | 2,150,168 | ||
Lines of credit, net of current portion | 939,781 | - | ||
Operating lease liability, net of current portion | - | 48,701 | ||
Deferred tax liability | 771,820 | 753,444 | ||
Total Liabilities | 13,265,820 | 12,997,621 | ||
Commitments and Contingencies (Note 13) | ||||
Stockholders' Equity: | ||||
Preferred stock, | ||||
no shares issued or outstanding | - | - | ||
Common stock, | ||||
43,579,557 shares and 43,579,557 shares issued and outstanding, respectively | 43,580 | 43,580 | ||
Additional paid-in capital | 23,590,204 | 23,590,204 | ||
Accumulated deficit | (27,630,142) | (25,972,402) | ||
Accumulated other comprehensive income | 11,855,428 | 11,576,219 | ||
Total Stockholders' Equity | 7,859,070 | 9,237,601 | ||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 21,124,890 | $ 22,235,222 | ||
CHINA PHARMA HOLDINGS, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
AND COMPREHENSIVE INCOME (LOSS) | ||||||||
(Unaudited) | ||||||||
For the Three Months | For the Nine Months | |||||||
Ended September 30, | Ended September 30, | |||||||
2020 | 2019 | 2020 | 2019 | |||||
Revenue | $ 2,400,667 | $ 2,376,844 | $ 7,935,345 | $ 7,875,525 | ||||
Cost of revenue | 2,353,471 | 2,004,085 | 6,543,912 | 6,682,688 | ||||
Gross profit | 47,196 | 372,759 | 1,391,433 | 1,192,837 | ||||
Operating expenses: | ||||||||
Selling expenses | 654,090 | 613,110 | 1,707,827 | 1,597,667 | ||||
General and administrative expenses | 290,586 | 333,833 | 1,001,590 | 1,097,200 | ||||
Research and development expenses | 37,628 | 39,716 | 116,491 | 175,642 | ||||
Bad debt (benefit) expense | 17,386 | 31,304 | 42,314 | 54,708 | ||||
Total operating expenses | 999,690 | 1,017,963 | 2,868,222 | 2,925,217 | ||||
Loss from operations | (952,494) | (645,204) | (1,476,789) | (1,732,380) | ||||
Other income (expense): | ||||||||
Interest income | 3,665 | 11,840 | 5,263 | 27,216 | ||||
Interest expense | (61,067) | (67,590) | (186,214) | (251,624) | ||||
Net other expense | (57,402) | (55,750) | (180,951) | (224,408) | ||||
Loss before income taxes | (1,009,896) | (700,954) | (1,657,740) | (1,956,788) | ||||
Income tax expense | - | - | - | - | ||||
Net loss | (1,009,896) | (700,954) | (1,657,740) | (1,956,788) | ||||
Other comprehensive income - foreign currency | ||||||||
translation adjustment | 470,445 | (909,889) | 279,209 | (885,188) | ||||
Comprehensive loss | $ (539,451) | $ (1,610,843) | $ (1,378,531) | $ (2,841,976) | ||||
Loss per share: | ||||||||
Basic and diluted | $ (0.02) | $ (0.02) | $ (0.04) | $ (0.04) | ||||
Weighted average shares outstanding | 43,579,557 | 43,579,557 | 43,579,557 | 43,579,557 | ||||
CHINA PHARMA HOLDINGS, INC. | ||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
(Unaudited) | ||||
For the Nine Months | ||||
Ended September 30, | ||||
2020 | 2019 | |||
Cash Flows from Operating Activities: | ||||
Net loss | $ (1,657,740) | $ (1,956,788) | ||
Depreciation and amortization | 1,978,363 | 2,261,800 | ||
Bad debt expense | 42,314 | 54,708 | ||
Inventory write off | - | 87,542 | ||
Changes in assets and liabilities: | ||||
Trade accounts and other receivables | (366,385) | (407,733) | ||
Advances to suppliers | (103,701) | (2,980) | ||
Inventory | 561,139 | 1,436,878 | ||
Trade accounts payable | (399,363) | 130,642 | ||
Accrued taxes payable | 123,921 | 23,321 | ||
Other payables and accrued expenses | (250,851) | (201,831) | ||
Change in bankers' acceptance notes payable | (109,663) | (773,264) | ||
Advances from customers | 119,199 | (12,670) | ||
Prepaid expenses | (314,361) | (9,211) | ||
Net Cash (Used in) Provided by Operating Activities | (377,128) | 630,414 | ||
Cash Flows from Investing Activities: | ||||
Purchases of property and equipment | (1,099,878) | (85,739) | ||
Net Cash Used in Investing Activities | (1,099,878) | (85,739) | ||
Cash Flows from Financing Activities: | ||||
Proceeds from lines of credit | 2,695,087 | - | ||
Payments of construction term loan | (2,145,389) | (2,188,463) | ||
Proceeds from related party loan | 162,090 | 674,405 | ||
Payments of related party loan | (77,530) | (209,726) | ||
Net Cash Provided by (Used in) Financing Activities | 634,258 | (1,723,784) | ||
Effect of Exchange Rate Changes on Cash | 4,472 | (30,604) | ||
Net Decrease in Cash, Cash Equivalents and Restricted Cash | (838,276) | (1,209,713) | ||
Cash, Cash Equivalents and Restricted Cash at Beginning of Period | 1,184,887 | 2,460,527 | ||
Cash, Cash Equivalents and Restricted Cash at End of Period | $ 346,611 | $ 1,250,814 | ||
Cash and Cash Equivalents | 346,611 | 761,606 | ||
Restricted cash | - | 489,208 | ||
Cash, Cash Equivalents and Restricted Cash at End of Period | $ 346,611 | $ 1,250,814 | ||
Supplemental Cash Flow Information: | ||||
Cash paid for income taxes | $ - | $ - | ||
Cash paid for interest | $ 176,055 | $ 241,465 | ||
Supplemental Noncash Investing and Financing Activities: | ||||
Issuance of banker's acceptances | $ - | $ 2,641 | ||
Accounts receivable collected with banker's acceptances | 394,393 | 532,537 | ||
Inventory purchased with banker's acceptances | 402,582 | 553,183 | ||
Right-of-use assets obtained in exchange for operating lease obligations | - | 231,130 | ||
View original content:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-reports-third-quarter-2020-financial-results-301172549.html
SOURCE China Pharma Holdings, Inc.
FAQ
What were China Pharma's Q3 2020 earnings results?
How does China Pharma's financial performance compare YoY for Q3 2020?
What was the total revenue for China Pharma in the first nine months of 2020?
What caused the increase in China Pharma's gross profit margin in 2020?
What was the cash position of China Pharma as of September 30, 2020?
